72 related articles for article (PubMed ID: 20599725)
1. The human cancer and stem cell marker podocalyxin interacts with the glucose-3-transporter in malignant pluripotent stem cells.
Schopperle WM; Lee JM; Dewolf WC
Biochem Biophys Res Commun; 2010 Jul; 398(3):372-6. PubMed ID: 20599725
[TBL] [Abstract][Full Text] [Related]
2. The TRA-1-60 and TRA-1-81 human pluripotent stem cell markers are expressed on podocalyxin in embryonal carcinoma.
Schopperle WM; DeWolf WC
Stem Cells; 2007 Mar; 25(3):723-30. PubMed ID: 17124010
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression.
Somasiri A; Nielsen JS; Makretsov N; McCoy ML; Prentice L; Gilks CB; Chia SK; Gelmon KA; Kershaw DB; Huntsman DG; McNagny KM; Roskelley CD
Cancer Res; 2004 Aug; 64(15):5068-73. PubMed ID: 15289306
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of cancer testis antigens modulates neural stem cell marker expression in glioblastoma tumor stem cells.
Low J; Dowless M; Shiyanova T; Rowlinson S; Ricci-Vitiani L; de Maria R; Pallini R; Stancato L
J Biomol Screen; 2010 Aug; 15(7):830-9. PubMed ID: 20639497
[TBL] [Abstract][Full Text] [Related]
5. The role of podocalyxin in health and disease.
Nielsen JS; McNagny KM
J Am Soc Nephrol; 2009 Aug; 20(8):1669-76. PubMed ID: 19578008
[TBL] [Abstract][Full Text] [Related]
6. The CDK inhibitor p27 enhances neural differentiation in pluripotent NTERA2 human EC cells, but does not permit differentiation of 2102Ep nullipotent human EC cells.
Bahrami AR; Matin MM; Andrews PW
Mech Dev; 2005 Sep; 122(9):1034-42. PubMed ID: 16023837
[TBL] [Abstract][Full Text] [Related]
7. Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin.
Sizemore S; Cicek M; Sizemore N; Ng KP; Casey G
Cancer Res; 2007 Jul; 67(13):6183-91. PubMed ID: 17616675
[TBL] [Abstract][Full Text] [Related]
8. Podocalyxin expression in malignant astrocytic tumors.
Hayatsu N; Kaneko MK; Mishima K; Nishikawa R; Matsutani M; Price JE; Kato Y
Biochem Biophys Res Commun; 2008 Sep; 374(2):394-8. PubMed ID: 18639524
[TBL] [Abstract][Full Text] [Related]
9. Enhanced podocalyxin expression alters the structure of podocyte basal surface.
Economou CG; Kitsiou PV; Tzinia AK; Panagopoulou E; Marinos E; Kershaw DB; Kerjaschki D; Tsilibary EC
J Cell Sci; 2004 Jul; 117(Pt 15):3281-94. PubMed ID: 15226400
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of the Pluripotent Stem Cell Marker Podocalyxin in Prostate Cancer.
Heath EI; Heilbrun LK; Smith D; Schopperle WM; Ju Y; Bolton S; Ahmed Q; Sakr WA
Anticancer Res; 2018 Nov; 38(11):6361-6366. PubMed ID: 30396958
[TBL] [Abstract][Full Text] [Related]
11. Specific knockdown of Oct4 and beta2-microglobulin expression by RNA interference in human embryonic stem cells and embryonic carcinoma cells.
Matin MM; Walsh JR; Gokhale PJ; Draper JS; Bahrami AR; Morton I; Moore HD; Andrews PW
Stem Cells; 2004; 22(5):659-68. PubMed ID: 15342930
[TBL] [Abstract][Full Text] [Related]
12. Cancer stem cell characteristics in retinoblastoma.
Seigel GM; Campbell LM; Narayan M; Gonzalez-Fernandez F
Mol Vis; 2005 Sep; 11():729-37. PubMed ID: 16179903
[TBL] [Abstract][Full Text] [Related]
13. Expression and localization of GLUT1 and GLUT12 in prostate carcinoma.
Chandler JD; Williams ED; Slavin JL; Best JD; Rogers S
Cancer; 2003 Apr; 97(8):2035-42. PubMed ID: 12673735
[TBL] [Abstract][Full Text] [Related]
14. Podocalyxin is expressed in normal and leukemic monocytes.
Riccioni R; Calzolari A; Biffoni M; Senese M; Riti V; Petrucci E; Pasquini L; Cedrone M; Lo-Coco F; Diverio D; Foà R; Peschle C; Testa U
Blood Cells Mol Dis; 2006; 37(3):218-25. PubMed ID: 17059890
[TBL] [Abstract][Full Text] [Related]
15. Isolation of human embryonal carcinoma stem cells by immunomagnetic sorting.
Przyborski SA
Stem Cells; 2001; 19(6):500-4. PubMed ID: 11713341
[TBL] [Abstract][Full Text] [Related]
16. Manipulation of human pluripotent embryonal carcinoma stem cells and the development of neural subtypes.
Stewart R; Christie VB; Przyborski SA
Stem Cells; 2003; 21(3):248-56. PubMed ID: 12743319
[TBL] [Abstract][Full Text] [Related]
17. Retinoic acid-induced differentiation of the developmentally pluripotent human germ cell tumor-derived cell line, NCCIT.
Damjanov I; Horvat B; Gibas Z
Lab Invest; 1993 Feb; 68(2):220-32. PubMed ID: 7680083
[TBL] [Abstract][Full Text] [Related]
18. Regulation of GLUT3 and glucose uptake by the cAMP signalling pathway in the breast cancer cell line ZR-75.
Meneses AM; Medina RA; Kato S; Pinto M; Jaque MP; Lizama I; García Mde L; Nualart F; Owen GI
J Cell Physiol; 2008 Jan; 214(1):110-6. PubMed ID: 17559076
[TBL] [Abstract][Full Text] [Related]
19. Embryonic stem cell markers expression in cancers.
Schoenhals M; Kassambara A; De Vos J; Hose D; Moreaux J; Klein B
Biochem Biophys Res Commun; 2009 May; 383(2):157-62. PubMed ID: 19268426
[TBL] [Abstract][Full Text] [Related]
20. Extracellular and transmembrane region of a podocalyxin-like protein 1 fragment identified from colon cancer cell lines.
Ito T; Maki N; Hazeki O; Sasaki K; Nekooki M
Cell Biol Int; 2007 Dec; 31(12):1518-24. PubMed ID: 17719804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
